AVEO Oncology, and LG Chem Company

1:45 PM - 2:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
AVEO Oncology, an LG Chem Company, is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO’s first commercial product, FOTIVDA® (tivozanib), received U.S. FDA approval in 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in 2017 in the European Union and countries in the territory of its partner Recordati/EUSA Pharma for the first line treatment of adult patients with advanced RCC. In addition to pursuing label expansion for FOTIVDA, AVEO is advancing its internal pipeline of product candidates, ficlatuzumab (Anti-HGF mAb), AV-203 (Anti-ERBB3 mAb), AV-353 (Anti-Notch 3 mAb) and AV-380 (Anti-GDF15 mAb). AVEO is actively seeking late-stage (Phase 3 – marketed) oncology assets for in-licensing/partnering opportunities.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ficlatuzumab, anti-HGF mAb
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
Chief Operating Officer
AVEO Oncology, Inc